News and Trends 9 May 2016
UK Biopharma joins Allergy race with good Phase II results for Hayfever
Allergy Therapeutics has gotten positive results for its phase II trial for birch pollen allergy – another win for their Pollinex platform. Based near Brighton (UK), Allergy Therapeutics has around 420 employees and has a market cap of €1.96M (£1.53M). Its focus is novel immunotherapies, with new technology for improving delivery and adjuvants – agents […]